http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Avant Technologies forms joint venture for diabetes cell therapy
-
Ardelyx CEO to speak at Wedbush nephrology conference
-
Majority of Canada’s drivers prioritize safety amid harsher winters despite rising cost of living: survey
-
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
-
National Committee for Quality Assurance (NCQA) Renews Healthmap Solutions’ Population Health Program Accreditation
-
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
-
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
-
Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment
-
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
-
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
-
Jupiter Power Announces Executive Leadership Transitions to Support Rapid Growth and Continued Operational Excellence
-
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
-
PKF O'Connor Davies Releases 21st Annual Architectural and Engineering Studies Highlighting Key Industry Trends
-
Stuhini Identifies High-Grade Copper-Gold Porphyry Target at Ruby Creek Project, BC
-
Family Heart Foundation® Launches New Initiative to Increase Understanding and Screening for High Lipoprotein(a), the Most Common Genetic Risk Factor for Premature Cardiovascular Disease
-
Ratio Therapeutics Announces the Appointment of Marcel Reichen as Chief Strategy Officer
-
Union Pacific Corporation CEO Jim Vena and CFO Jennifer Hamann to Address the Baird 2025 Global Industrial Conference
-
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025
-
Realbotix to Exhibit at CES 2026 with Expanded Lineup of AI-Powered Humanoid Robots
-
1847 Holdings Files Lawsuit Against Matthew Miller and Strategic Risk LLC for Commercial Disparagement and Trade Libel
-
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
-
Bioventus Reports Third Quarter Financial Results
-
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
-
Bitcoin Bancorp Partners with Sailo Technologies to Launch Revolutionary Bitcoin Treasury Management Platform Amid Surge in Corporate Adoption
-
QOL Medical to acquire Evoke Pharma for $11 per share in cash
-
GENPREX receives European patent intent for cancer gene therapy combination
-
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer
-
Magnet Biomedicine Appoints Bharat Reddy, Ph.D., as Chief Business Officer
-
Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical
-
Compass, Inc. Reports Record Third Quarter 2025 Results
-
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
-
Zoetis Announces Third Quarter 2025 Results
-
GreyNoise Integrates with CrowdStrike Falcon Next-Gen SIEM to Unify Network Intelligence and Accelerate SOC Transformation
-
Hagerty Reports Third Quarter 2025 Results; Increases 2025 Outlook
-
Merck receives $700 million from Blackstone for cancer drug development
-
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
-
BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease
-
Merck assumes full rights to MK-8690 drug after $150 million Falk deal
-
Descartes’ Study Finds 67% of Freight Forwarders and Customs Brokers View Technology as Fundamental to Growth
-
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
-
Denison Mines faces judicial review over Wheeler River uranium project
-
Denison Acknowledges Application for Judicial Review Regarding Provincial Environmental Assessment Approval for Wheeler River
-
22nd Century Group Reports Third Quarter 2025 Financial Results
-
BROAD ARROW’S INAUGURAL ZÜRICH AUCTION ACHIEVES OVER CHF 22M WITH 87 PERCENT SELL-THROUGH RATE
-
Breakthrough in 5G FWA to Bring High-Speed Broadband to MDUs
-
SnapLogic Eliminates Legacy Migration Costs by up to 80% with SnapLogic Intelligent Modernizer
-
SnapLogic Accelerates Enterprise AI Adoption with New Capabilities for Agents, MCP, and Enhanced AI Governance
-
Bitget Launches Institutional Financing Program Offering Interest-Free 2M USDT to Boost Altcoin Liquidity
-
Golden Cariboo Resources Commences Autumn Drill Campaign at the Quesnelle Gold Quartz Mine Property
-
Star Copper Kicks Off Inaugural Drilling at Star North Target


